NASDAQ Company Wanted

We are negotiating for a NASDAQ Company acquisition using our First FDA target Cancer Drug ($25m+ valuation) to vend in.

Mission & Achievements:

a. Critical Mass Market Opportunity/Worldwide
b. Cancer Drug Valuations & Pipeline Competitive Edge / Contact
c. Developing Low-cost, Cancer Killing Treatments.
d. HARVARD Award-Winning Research, TOP Ranked
e. Published results in Frontiers in Oncology TOP 97%.
f. 2018 Harvard GHC Industry Leader Award

Massive Current Valuation & Growth Potential:

a. $25 Million – Today Cancer Drug Valuation, each one
b. $59 Million after FDA IND # Application Approval, each one
c. $1.1 Billion after Killing Cancer During Clinical Trials, each one
d. $5–50 Billion – Successful Market Entry Potential, each one

Structure Choices:

a. Trading NASDAQ SPAC, First Best Option.
b. Current trading NASDAQ purchase option agreement.
c. NASDAQ Partnership (CRADA) & purchase option agreement.

After acquisition we activate the “Three punch Knock out” and attain our High-Goals Success:

a. Filing for the FDA IND#. (First Cancer Drug Valuation today $25mm+, each one)
b. Beginning Phase 1 Clinical Trials. (First Cancer Drug Valuation jumps to $55mm+)
c. Killing the first cancers during the FDA Clinical Trials. (Valuation jumps to $1B+)

Our 3 Main Success Points:

1. Current Valuation for each Cancer Drug we own (2x) ready for the FDA IND# Application process
($25 million+) and the massive multiplied future projected FDA success valuations. (10x-100x plus)

2. Built-in mass-investor NASDAQ market distribution for stock market liquidity. Inside team of NASDAQ Market Distribution Experts, $1.00+ Experts, and $5.00 - $100.00+ Experts inducing millions of shares
trading volume per day.

3. Full Pipeline of Pharmaceutical Drugs Cancers & Neurological conditions; One at a time roll-in for
Maximum Market Reactions and Growth.

Competative Edge:

a. HARVARD-Validated Proof of Cancer Elimination
b. TOP 97% Reports (2x) Frontiers on Oncology
c. Expert Teams, Doctors & Scientists (100 years+)
d. Top Universities & Institutional Research Teams
e. Low-cost Drugs vs. $200K+ competitor drugs
f. FDA Fast-Track possible (24 months vs. 7 years)
g. NASDAQ Market Distribution Expert Teams

Ready to go now!

The first NASDAQ announcements begin immediately with the Cancer Drug Acquisition and then start the Pharmacokinetics to apply for FDA IND#.

a. Filing the FDA IND# with completed Pharmacokinetics.
b. Beginning Phase 1 Clinical Trials.
c. Killing Cancers during the FDA Clinical Trials.